https://www.empiri.co/news/deals-with-empirico-and-aro-to-help-ionis-bring-new-targets-tissues-to-early-stage-pipeline/ 2023-11-22T18:15:27+00:00 monthly 0.6 https://www.empiri.co/news/empirico-raises-17m-inks-3-year-antisense-collaboration-with-ionis/ 2023-11-22T18:16:00+00:00 monthly 0.6 https://www.empiri.co/news/ionis-finds-new-partner-in-a-young-biotech-and-its-hopeful-founder/ 2023-11-22T18:08:52+00:00 monthly 0.6 https://www.empiri.co/news/empirico-scores-660m-deal-with-ionis-and-lands-a-series-a-2-fundraiser/ 2023-12-12T19:43:23+00:00 monthly 0.6 https://www.empiri.co/news/empirico-inks-drug-target-discovery-alliance-with-antisense-drug-firm-ionis/ 2023-11-22T18:21:15+00:00 monthly 0.6 https://www.empiri.co/news/gsk-adds-to-copd-drug-push-with-empirico-deal/ 2025-10-31T14:40:29+00:00 monthly 0.6 https://www.empiri.co/news/gsks-respiratory-pipeline-adds-an-early-stage-drug-offering-a-novel-approach-to-copd/ 2025-10-31T14:40:17+00:00 monthly 0.6 https://www.empiri.co/news/gsk-expands-respiratory-pipeline-with-sirna-pact/ 2025-10-31T14:39:52+00:00 monthly 0.6 https://www.empiri.co/news/gsk-strikes-again-adding-copd-candidate-in-745m-deal/ 2025-10-31T14:27:19+00:00 monthly 0.6 https://www.empiri.co/news/gsk-snaps-up-empiricos-sirna-copd-asset-in-745m-deal/ 2025-10-31T14:27:10+00:00 monthly 0.6 https://www.empiri.co/news/gsk-to-license-empiricos-copd-candidate-for-85m-upfront/ 2025-10-31T14:39:42+00:00 monthly 0.6 https://www.empiri.co/news/gsk-pens-745m-deal-for-phase-1-drug-that-hits-sweet-spots-of-copd-oligonucleotides/ 2025-10-31T14:30:06+00:00 monthly 0.6